Mechanism of resistance to cetuximab therapy in colorectal cancer
Open Access
- 1 September 2012
- journal article
- Published by Taylor & Francis Ltd in mAbs
- Vol. 4 (5), 553-554
- https://doi.org/10.4161/mabs.21311
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerNature, 2012
- Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancerNature Medicine, 2012
- A new synthesis for antibody-mediated immunityNature Immunology, 2011
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody CetuximabScience Translational Medicine, 2011
- 2nd Charles Richet et Jules Héricourt WorkshopmAbs, 2011
- Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-GalactoseThe New England Journal of Medicine, 2008
- The Immunoglobulin Heavy Chain Constant Region Affects Kinetic and Thermodynamic Parameters of Antibody Variable Region Interactions with AntigenJournal of Biological Chemistry, 2007
- A Genetic Marker of Human IgE Heavy Chains, Em(1)1Vox Sanguinis, 1984
- An idiotypic determinant formed by both immunoglobulin constant and variable regionsNature, 1983
- Antibody to Hereditary Human Gamma-Globulin (Gm) Factor Resulting from Maternal-Fetal IncompatibilityScience, 1964